Aviva PLC Has $477,000 Holdings in Progyny, Inc. $PGNY

Aviva PLC trimmed its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 23.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,704 shares of the company’s stock after selling 6,753 shares during the quarter. Aviva PLC’s holdings in Progyny were worth $477,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Cerity Partners LLC boosted its stake in shares of Progyny by 116.9% during the 1st quarter. Cerity Partners LLC now owns 28,881 shares of the company’s stock worth $645,000 after acquiring an additional 15,563 shares in the last quarter. CWM LLC lifted its holdings in Progyny by 268.8% in the 1st quarter. CWM LLC now owns 23,479 shares of the company’s stock worth $525,000 after purchasing an additional 17,112 shares during the last quarter. Guidance Capital Inc. boosted its position in Progyny by 13.7% during the first quarter. Guidance Capital Inc. now owns 25,018 shares of the company’s stock worth $581,000 after purchasing an additional 3,017 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Progyny during the first quarter valued at approximately $668,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Progyny in the first quarter valued at approximately $1,946,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Trading Up 1.5%

Shares of NASDAQ:PGNY opened at $24.42 on Friday. The firm has a market capitalization of $2.11 billion, a PE ratio of 38.76, a PEG ratio of 2.05 and a beta of 1.29. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $26.76. The business’s 50 day moving average is $20.95 and its 200-day moving average is $21.89.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.06. The firm had revenue of $313.35 million for the quarter, compared to analyst estimates of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. On average, sell-side analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on PGNY. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Tuesday. Canaccord Genuity Group boosted their target price on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research report on Wednesday, August 20th. Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a report on Wednesday, October 8th. KeyCorp upgraded Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price objective on the stock in a research note on Tuesday. Finally, Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Progyny has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 5,395 shares of company stock worth $124,211 in the last three months. 9.40% of the stock is owned by company insiders.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.